ArticleScientific reports2026
Targeting bacitracin resistance-associated histidine kinase (BraS) in MRSA with isatin and indazole derivatives.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The BraSR two-component system plays a crucial role in bacitracin sensing and resistance in Staphylococcus aureus, making the BraS histidine kinase an attractive antibacterial target. In this study, we applied a structure-based drug discovery approach to identify ATP competitive isatin and indazole based hits targeting the BraS kinase domain. A two-stage virtual screening workflow, involving molecular docking, molecular dynamics simulations, MM-PBSA freeenergy estimation, and interaction analyses was used to prioritize compounds with favourable relative binding profiles within each series. Computational analyses suggested that several isatin and indazole derivatives adopt stable binding modes within the ATP-binding pocket of BraS and exhibit favourable predicted binding energetics compared to other screened compounds. Based on these in silico rankings, three isatin and three indazole derivatives were selected for chemical synthesis and experimental evaluation. Interactions between the test compounds and the recombinant BraS kinase domain were evaluated using microscale thermophoresis. Several compounds including IS7, IS12, IN16 and IN21 shows measurable binding affinities in the nanomolar range. The isatin-series compound IS12 exhibited a dissociation constant (Kd) of 2nM while IN21 from the indazole series exhibited a Kd of 251nM against the BraS kinase domain. In parallel, selected compounds were evaluated for their effects on biofilm formation using a crystal violet assay. Although a reduction in biofilm biomass was observed at specific concentrations, these effects are interpreted as indirect modulation of regulatory pathways associated with BraSR signalling rather than direct antibiofilm activity. Overall, this study identifies isatin and indazole derivatives as promising ATP-competitive hits that bind to the BraS kinase domain and provides a framework for further structure-guided optimization. However, functional inhibition, cellular efficacy, and pharmacological properties remain to be established through future biochemical and in vivo studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.